GT Biopharma, Inc.
GTBP · XNASCIK 109657fmd_0F2B69HFF5E3MBJKMP4PZEFDHV制造业 · 医药制剂模板: 标准
覆盖范围: 2010年1月01日 至 2026年6月30日，共 65 个期间
| 项目 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 营业总收入 | 0 | 0 | – | 0 | 0 | – | – | – | – | – |
| 营业成本 | 0 | 0 | – | – | – | – | – | – | – | – |
| 毛利润 | 0 | 0 | – | – | – | – | – | – | – | – |
| 研发费用 | 1 | 1 | 9 | 2 | 0 | 10 | 9 | 6 | 6 | 3 |
| 销售、一般及管理费用 | 8 | 135 | 12 | 10 | 6 | 48 | 12 | 7 | 9 | 9 |
| 营业费用合计 | 9 | 136 | 250 | 16 | – | 58 | 21 | 14 | – | – |
| 营业利润 | (9) | (136) | (250) | 16 | (7) | (58) | (21) | (14) | (14) | (12) |
| 利息费用 | 7 | 9 | 9 | (2) | (3) | 1 | 0 | 0 | – | 0 |
| 其他营业外收入（支出） | 19 | (9) | (9) | 23 | (22) | (0) | 0 | 6 | 1 | (16) |
| 税前利润 | 10 | (144) | (259) | (39) | – | – | – | – | – | – |
| 所得税费用 | 0 | 0 | 0 | 0 | – | – | – | – | – | – |
| 持续经营净利润 | 10 | (144) | (259) | (39) | – | – | – | – | – | – |
| 净利润 | 10 | (144) | (259) | (39) | (28) | (58) | (21) | (8) | (13) | (28) |
| 归属于普通股股东的净利润 | – | – | – | – | – | – | – | – | (13) | (34) |